[go: up one dir, main page]

WO1996001846B1 - Proinsulin peptide compounds for detecting and treating type i diabetes - Google Patents

Proinsulin peptide compounds for detecting and treating type i diabetes

Info

Publication number
WO1996001846B1
WO1996001846B1 PCT/US1995/008596 US9508596W WO9601846B1 WO 1996001846 B1 WO1996001846 B1 WO 1996001846B1 US 9508596 W US9508596 W US 9508596W WO 9601846 B1 WO9601846 B1 WO 9601846B1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
proinsulin
arg
ser
amino acid
Prior art date
Application number
PCT/US1995/008596
Other languages
French (fr)
Other versions
WO1996001846A1 (en
Filing date
Publication date
Application filed filed Critical
Priority to DK95926642T priority Critical patent/DK0788512T3/en
Priority to EP95926642A priority patent/EP0788512B1/en
Priority to DE69508605T priority patent/DE69508605T2/en
Priority to MX9700198A priority patent/MX9700198A/en
Priority to JP8504435A priority patent/JPH10505821A/en
Priority to AU30947/95A priority patent/AU3094795A/en
Publication of WO1996001846A1 publication Critical patent/WO1996001846A1/en
Publication of WO1996001846B1 publication Critical patent/WO1996001846B1/en

Links

Abstract

Proinsulin peptide compounds that modulate an immunological response by T cells of Type I diabetic subjects are disclosed. The proinsulin peptide compounds of the invention are preferably derived from a region of proinsulin that spans the junction between the B chain and C peptide of proinsulin. Pharmaceutical compositions comprising the proinsulin peptide compounds are also disclosed. An immunological response to a proinsulin peptide compound of the invention can be used as an indicator of Type I diabetes in a subject. Accordingly, the invention provides diagnostic assays for Type I diabetes using the proinsulin peptide compounds. Methods for inhibiting the development or progression of Type I diabetes in a subject by administering a proinsulin peptide compound are also disclosed.

Claims

-46-
AMENDED CLAIMS
[received by the International Bureau on 5 February 1996 (05.02.96); original claims unchanged; new claims 33-42 added; (2 pages)]
31. The method of claim 29, wherein the agent is a compound derived from human proinsulin.
32. The method of claim 29, wherein the compound comprises an amino acid sequence comprising the formula:
Yl-P^aa)n-(SerTrιx)-Pro-Lys-(Ser/Thr)-Arg-Arg-(Glu/Asp)-(Zaa)m-Y2
wherein Xaa and Zaa, which may or may not be present, represent amino acid residues, n and m are integers from 1 to 15, Yi is hydrogen or an amino-derivative group and Y2 is hydrogen or a carboxy-derivative group.
33. Use of a proinsulin peptide compound which modulates an immunological response by T cells of Type I diabetic subjects for the manufacture of a medicament for inhibiting the development or progression of Type I diabetes in a subject.
34. The use of claim 33, wherein the compound is identical or substantially similar to a region of proinsulin that spans the junction between the B chain and the C peptide of proinsulin.
35. The use of claim 33, wherein the compound is derived from human proinsulin.
36. The use of claim 33, wherein the compound comprises an amino acid sequence comprising the formula:
Y 1 -(Xaa)n-(Ser Tr-r)-Pro-Lys-(Ser Thr)-Arg-Arg-(GluAsp)-(Zaa)rn- Y2
wherein Xaa and Zaa, which may or may not be present, represent amino acid residues, n and m are integers from 1 to 15, Y1 is hydrogen or an amino-derivative group and Y2 is hydrogen or a carboxy-derivative group.
37. The use of claim 36, wherein the compound is 10-35 amino acids in length.
38. The use of claim 36, wherein the compound is 10-20 amino acids in length.
39. The use of claim 36, wherein the compound is 12-17 amino acids in length.
40. The use of claim 33. where in the compound comprises an amino acid sequence: -47-
Y i -Gly-Phe-Phe-Tyr-(Ser Trιr)-Pro-Lys-(Ser/Trιr)-Arg-Arg-(Glu/Asp)-Ala- Glu-(Glu/Asp)-Leu-Gln-Val-Gly-Y2
41. The use of claim 33 , wherein the compound is a modified form of a proinsulin peptide.
42. The use of claim 33, which comprises a tolerogenic amount of the proinsulin peptide compound.
PCT/US1995/008596 1994-07-08 1995-07-07 Proinsulin peptide compounds for detecting and treating type i diabetes WO1996001846A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK95926642T DK0788512T3 (en) 1994-07-08 1995-07-07 Proinsulin Peptide Compounds for the Detection and Treatment of Type I Diabetes
EP95926642A EP0788512B1 (en) 1994-07-08 1995-07-07 Proinsulin peptide compounds for detecting and treating type i diabetes
DE69508605T DE69508605T2 (en) 1994-07-08 1995-07-07 PROINSULIN PEPTIDE COMPOUNDS FOR DETECTING AND TREATING TYPE I DIABETES
MX9700198A MX9700198A (en) 1994-07-08 1995-07-07 Proinsulin peptide compounds for detecting and treating type i diabetes.
JP8504435A JPH10505821A (en) 1994-07-08 1995-07-07 Proinsulin peptide compounds for the detection and treatment of type I diabetes - Patents.com
AU30947/95A AU3094795A (en) 1994-07-08 1995-07-07 Proinsulin peptide compounds for detecting and treating type i diabetes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27222094A 1994-07-08 1994-07-08
US08/272,220 1994-07-08
US47270495A 1995-06-06 1995-06-06
US08/472,704 1995-06-06

Publications (2)

Publication Number Publication Date
WO1996001846A1 WO1996001846A1 (en) 1996-01-25
WO1996001846B1 true WO1996001846B1 (en) 1996-03-07

Family

ID=26955374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/008596 WO1996001846A1 (en) 1994-07-08 1995-07-07 Proinsulin peptide compounds for detecting and treating type i diabetes

Country Status (12)

Country Link
US (1) US20030220229A1 (en)
EP (1) EP0788512B1 (en)
JP (1) JPH10505821A (en)
CN (1) CN1157621A (en)
AT (1) ATE178074T1 (en)
AU (1) AU3094795A (en)
CA (1) CA2194548A1 (en)
DE (1) DE69508605T2 (en)
DK (1) DK0788512T3 (en)
ES (1) ES2130629T3 (en)
MX (1) MX9700198A (en)
WO (1) WO1996001846A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637130T2 (en) 1995-02-20 2008-02-21 The Walter And Eliza Hall Institute Of Medical Research, Parkville IMMUNOREACTIVE AND IMMUNOTHERAPEUTIC MOLECULES THAT INTERACT IN INDIVIDUALS WITH INSULIN-DEPENDENT DIABETES MELLITUS
SE520392C2 (en) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specific peptides for the treatment of diabetes mellitus
AUPO269996A0 (en) * 1996-10-01 1996-10-24 Walter And Eliza Hall Institute Of Medical Research, The A method of prophylaxis and treatment
ES2331342B1 (en) * 2006-05-22 2010-10-13 Consejo Superior Investg.Cientificas USE OF PROINSULIN FOR THE PREPARATION OF A NEUROPROTECTING PHARMACEUTICAL COMPOSITION, THERAPEUTIC COMPOSITION CONTAINING IT AND ITS APPLICATIONS.
CN103630692B (en) * 2013-06-02 2015-05-06 马鞍山国声生物技术有限公司 Colloidal gold immunochromatography kit for rapidly detecting urine C peptide and detecting method thereof
WO2015057968A2 (en) * 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
GB2523399B (en) * 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
GB2559499A (en) * 2014-02-25 2018-08-08 Orban Tihamer Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes
WO2025035125A1 (en) * 2023-08-10 2025-02-13 The Curators Of The University Of Missouri Suppression of type 1 diabetes by intrathymic il-4

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5210872B2 (en) * 1973-07-14 1977-03-26
US4308181A (en) * 1980-12-08 1981-12-29 American Home Products Corporation Polypeptide compositions
US4652548A (en) * 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
NL9001083A (en) * 1990-05-04 1991-12-02 Rijksuniversiteit BETA-CELL ANTIGEN.
CA2089742C (en) * 1990-08-17 2002-05-14 Mark A. Atkinson Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus

Similar Documents

Publication Publication Date Title
Becker et al. Action of derivatives of. mu.-conotoxin GIIIA on sodium channels. Single amino acid substitutions in the toxin separately affect association and dissociation rates
WO1996001846B1 (en) Proinsulin peptide compounds for detecting and treating type i diabetes
ATE140969T1 (en) IL-3 WITH ADDITIONAL CYSTEINE RESIDUE AND CHEMICAL MODIFICATIONS THEREOF
Kern et al. Biosynthesis of skin collagens in normal and diabetic mice
Witkop Chemical Cleavage of Proteins: Selective fragmentations and modifications reveal structure.
ES8501364A1 (en) Peptides.
Huisman et al. Amino-acid composition of four different kinds of human haemoglobin
EP0741869B1 (en) Specific binding substances for antibodies and their use for immunoassays or vaccines
HUT53664A (en) Process for producing enzyme inhibiting amino acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
MX9700198A (en) Proinsulin peptide compounds for detecting and treating type i diabetes.
Air et al. Studies on Marsupial Proteins IV. Amino Acid Sequence of Myoglobin From the Red Kangaroo, Megaleia Rufa
DE69325943T3 (en) Synthetic polypeptides of the hepatitis C virus, useful for the detection of the virus
NO955067L (en) FVII / TF peptides
AU7597994A (en) Peptide having inflammation affinity and radioactive diagnostic containing the same
Kurahashi et al. Amylase secretion by parotid glands and pancreas of diabetic rats during feeding
RODEWALD et al. Homeothermic fish and hemoglobin: primary structure of the hemoglobin from bluefin tuna (Thunnus thynnus, Scromboidei)
KR860000072A (en) Manufacturing method of gonococcal vaccine
Motoyoshi et al. Resolution of the Polypeptide Chain Elongation Factor-1βγ into Subunits and Some Properties of the Subunits
Markussen et al. Human monocomponent insulin: Chemistry and characteristics
WO1997039029A3 (en) An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
CA2136565A1 (en) Polypeptide of Protein p140 and DNAs Encoding It
WO1986001209A3 (en) New p-phenylenediamine peptides and reactance containing them for the determination of proteases of the blood coagulation system
Knecht et al. Degradation of glomerular basement membrane in diabetes: I. Susceptibility of diabetic and nondiabetic basement membrane to proteolytic degradation of isolated glomeruli
IE841192L (en) Preparation of steroid esters
Nute et al. Complete sequence of the γ chain from the fetal hemoglobin of the baboon, Papio cynocephalus